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absorption . A simple method to assess PK AUC of single dose/
24hrs of IV BU in pediatric patients is described. Patients who
signed informed consent were enrolled. The regimen consisted of
test dose of IV BU (0.8mg/kg) as a single dose day -10, Fludarabine
30mg/m2/day on days –10 to –6, followed by BU 3.2 mg per
Kg/day on days –5 and –4 and rabbit ATG 2mg/kg on days –4 to
–1. Phenytoin prophylaxis was given for 4 days. Cells were infused
on day 0. There were 5 patients with a median age 8.0 (0.5-16
years);. The median weight was 22.6 (range 4.3-45.4) Kg. Patients
diagnoses include: Omenn’s syndrome, Neuroblastoma, ALL,
CML, and X linked lymphoproliferative disease. Samples were
obtained at 2, 4, 8 and 12 hrs and submitted to the Fred Hutchin-
son Cancer Center for determination of the AUC. An AUC of
800-1200 was targeted for the test dose. The median measured
AUC was 1034 (816-1315) uMol*min; the clearance was 3.1 (2.4-
3.9) (ml/min) kg. The target AUC equals the AUC of the test dose
multiplied by 4. The dose of 3.2mg/Kg/q24 hrs was administered
and the target AUC was 3800-4200. The measured AUC median
was 3590 (2307-4097) uMol*min and the clearance 3.4 (3-4.2)(ml/
min)/kg, Dose adjustment of 10% lower dose on days –5, –4 was
made on one patient who had a high AUC, the modiﬁcation resulted
in a lower AUC. No instances of hepatic veno-occlusive disease or
seizures developed. Neutrophil and platelet engraftment was prompt
in 3/3 evaluable patients. Three of the patients have achieved full
chimerism. In conclusion, PK of a test dose of 0.8 mg/Kg of IV BU
multiplied by 4 appears to be predictive of the PK for a single daily
dose of IV BU in pediatric patients undergoing a RI HSCT.
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OUTCOME OF TRANSPLANTATION WITH UNRELATED DONOR BONE
MARROW IN CHILDREN WITH SEVERE THALASSEMIA
Pakakasama, S.1,3, Hongeng, S.1,3, Chaisiripoomkere, W.2,3, Chuan-
sumrit, A.1, Ungkanont, A.2,3, Jootar, S.2,3 1. Department of Pediatrics;
2. Department of Internal Medicine; 3. Bone Marrow Transplant Pro-
gram, Faculty of Medicine, Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand
About 70% of thalassemic patients lack HLA-identical family
members to be suitable donors for bone marrow transplantation
(BMT). To increase therapeutic opportunity for these patients, we
have performed BMT from unrelated donors to children with
severe beta-thalassemia at our institute. The objective of this study
is to determine the outcomes of patients who underwent unrelated
BMT for severe beta-thalassemia. There were 11 patients; 6 ho-
mozygous beta-thalassemia, and 5 severe beta-thalassemia/Hb E
disease. The median age was 3 years (range, 1-11 years). Prepara-
tive regimen consisted of busulfan, cyclophosphamide, and rabbit
anti-thymocyte globulin. The patients received bone marrow from
unrelated donor (6/6 HLA-matched  10, 5/6  1) with a median
CD 34 cell dose of 3.3  106 cells/kg (range, 0.8-6.9  106
cells/kg). GVHD prophylaxis was cyclosporin (CSA) and myco-
phenolate moteﬁl (MMF) (n  7), or tacrolimus (FK 506) and
MMF (n  1), or FK 506 and methotrexate (n  3). The median
day of neutrophil and platelate engraftment was 16 and 26, respec-
tively. Ten patients engrafted with full donor chimerism, one with
mixed chimerism. Six patients (55%) had acute GVHD (gr I  1,
gr II-IV  5). Limited chronic GVHD appeared in 5 patients
(45%). CMV reactivation was detected in 3 patients, no CMV
disease. All patients were alive and well with a median follow-up
time of 16 months (range, 9-30 months). Our data demonstrate
that unrelated BMT could be considered as an optional therapy for
children with severe beta-thalassemia.
205
REDUCED INTENSITY CONDITIONING AND ALLOGENEIC STEM CELL
TRANSPLANTATION (RIALLOSCT) FROM UNRELATED CORD BLOOD
AND MATCHED FAMILY DONORS IN CHILDREN AND ADOLESCENT
RECIPIENTS RESULTS IN SUSTAINED DONOR CHIMERISM
Del Toro, G., Satwani, P., Harrison, L., Cheung, Y.-K., Bradley, M.B.,
George, D., Yamashiro, D., Garvin, J., Skerrett, D., Bessmertny, O.,
Wolownik, K., Wischhover, C., van de Ven, C., Cairo, M.S. Children’s
Hospital of New York-Presbyterian, Columbia University, New York, NY
Mixed and ultimately complete donor chimerism have been
achieved in adults following RIAlloSCT from matched related and
unrelated donors (Slavin et al, Blood:99:1071, 2002). However,
there is little data regarding the use of a RIAlloSCT approach in
pediatric recipients. We determined the degree of chimerism by
unique VNTR and STR alleles after RIAlloSCT in children fol-
lowing matched family donor (MFD) stem cell & unrelated um-
bilical cord blood (UCB) transplants. Donors: 14 UCB, 2 BM, 4
PBSC, and 1 BM  PBSC. RIC: Busulfan (Bu)/Fludarabine (Flu)/
r-ATG (N  11); Bu/Flu (N  1); Bu/Flu/Alemtuzumab (N  2);
Flu/Cyclophosphamide (Cy)/r-ATG (N  4); Flu/Melphalan/h-
ATG (N  1); 200 cGy TBI/Flu/Cy/h-ATG (N  1); and Flu/
Cy/etoposide/r-ATG (N  1); GVHD prophylaxis: FK-506 and
MMF. Demographics: median age 13 (0.5-21) yrs; HD (6), NHL
(1), neuroblastoma (2), Wilms’ tumor (1), CML (1), AML (1),
MDS (1), Wiskott-Aldrich syndrome (1), -thal (2), aplastic anemia
(2), Fanconi anemia (1), HLH (1). The UCB median cell dose was
4.3 (0.9-10.8)  107 nc/kg and 1.9 (0.3-6.9)  105 CD34/kg. The
BM/PBSC cell dose was 8.3 (4.7-18.9)  108 nc/kg and 5.0 (4.6-
6.4) 106 CD34/kg. MFD vs. UCB median time to ANC500
2d was 14 (8-22) days vs.18 (2-45) days and platelet count 20,000
untransfused  7d was 11 (8-22) days vs. 21 (6-170) days. Maximal
donor chimerism (MDC) for UCB was 100% for 8 pts, 98% for 1
pt, 95% for 1 pt, 55% for 1 pt (died of PD on day79), and 0% for
3 pts. For related MFD, MDC was 100% for 6 pts, 65% for 1 pt
and 55% for 1 pt. Primary graft failure occurred in 3 patients
(-Thal, MDS, HLH). Secondary graft failure occurred in 2 patients
(AA and -Thal). Grade 4 toxicities were: 1 transaminitis, 1 hyper-
glycemia, and 1 leukoencephalopathy. Opportunistic infectious
complications included: candidemia (N 3), aspergillosis (N 1),
adenovirus (N 4),Mycobacterium spp. (N 2) and one subclinical
CMV infection. The probability of AGVHD grade II-IV in UCB
vs. MFD was 30.1% vs. 46.5%. The overall probability of
CGVHD was 10% at day 200. The probability of 1-yr OS is 69%.
RIAlloSCT in children and adolescents appears feasible and toler-
able and results in 70% achieving 90% sustained mixed donor
chimerism within 2 months. The risk of graft failure following
RIAlloSCT in children and adolescents is similar to adults (Maris
et al, Blood 102:2021, 2003) and occurs mainly in non-malignant
diseases (-Thal, MDS, AA, HLH).
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NONMYELOABLATIVE TRANSPLANT IN CHILDHOOD DISEASES
Chik, K.W., Li, C.K., Shing, M.M.K., Lee, V., Yuen, P.M.P. Depart-
ment of Paediatrics, The Chinese University of Hong Kong, Hong Kong
SAR, China
Nonmyeloablative transplant provides a cure for seriously ill
children with lesser degree of toxicity. We report our experience
on ﬂudarabine based preparatory regimen in 12 subjects (M:F 
5:7, median age 95 months) from September 1999 to June 2002.
There were acute lymphoblastic leukemia(1), acute myeloid leuke-
mia(1), chronic myeloid leukemia(1), severe aplastic anemia(5),
Fanconi anemia(1), Wiskott Aldrich syndrome(1), Omenn syn-
drome(1) and I cell disease(1). They were either with complications
from prior intensive chemotherapy, second transplant, mismatched
related donors/cord blood or matched unrelated donors. The con-
ditioning regimen consists of ﬂudarabine 30mg/m2 for 5 days from
day-8, cyclophosphamide 60mg/kg for 2 days from day-3 and
anti-thymocyte globulin 30mg/kg (10mg/kg for HLA-identical
related transplant) for 3 days from day-3. The donor graft was not
T cell depleted with median CD34 count of 4.12  106/kg. The
neutrophil engraftment occurred at median of 16 days (9-29),
platelet transfusion independence at median of 21 days and red
blood cell transfusion independence at median of 23 days. No
conﬁrmed septicemia was noted. One patient had herpes simplex
encephalitis on day 32 with signiﬁcant physical handicap. No other
major toxicity was noted. Three developed mixed chimerism with
subsequent conversion to complete chimerism by either with-
drawal of immunosuppressives or donor leucocyte infusion. The
patient with I cell disease had stable mixed chimerism and re-
mained clinically stable. Two had mixed chimerism and then re-
jection of the donor graft. The remaining 6 remained in complete
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chimerism. Acute graft-versus-host disease occurred in 9 subjects
(2 with grade I, 6 with grade II, 1 with grade III). Chronic
graft-versus-host disease occurred in 8 subjects (5 limited, 3 ex-
tensive). The overall survival was 66% with a median follow up
of 32 months. Four subjects died due to relapse of primary dis-
ease (2 leukemia subjects and 1 Omenn syndrome) and acineto-
bacter septicaemia (1). In conclusion, among malignant diseases,
only the patient with chronic myeloid leukemia survived. Chi-
merism monitoring is essential for post-transplant manage-
ment of persistent detectable recipient hematopoietic cells.
The encouraging result in nonmalignant condition suggests the
beneﬁt of reduced transplant related toxicity and satisfactory
engraftment.
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ALLOGENEIC BLOOD AND MARROW TRANSPLANTATION IN THALAS-
SEMIA MAJOR CLASS 3: AN EXPERIENCE OF IRAN
Ghavamzadeh, A., Iravani, M., Gholibeikian, S., Moradiseresht, M.,
Heydari, P. Hematology-Oncology and BMT Research Center, Tehran,
Islamic Republic of Iran
Objective: Our aim for this study was to describe the outcome of
blood and marrow transplantation in patients with class 3 thalas-
semia major. Method and patients: Since December 1992 till
October 2002, forty-three patients with thalassemia class 3 re-
ceived blood and marrow transplantation from their HLA-identi-
cal siblings. Median age at time of transplantation was 8 years (age
range  3-17), Male/Female  24/19. Twenty-eight patients re-
ceived bone marrow and ﬁfteen patients received peripheral blood
stem cell transplantation. Conditioning regimen was cyclophosph-
amide 40 mg/kg/day (from day–5 to -1) and busulfan 4 mg/kg/day
(from day –9 to -6). GVHD prophylaxis regimen was cyclosporine
A 3mg/kg /day/iv (from day –2 to 5) then 12.5 mg/kg/day/po
(from day5) and methotrexate 10mg/m2 (day1), 6mg/m2 (days
3, 6). Results: Median time of absolute neutrophil count 
0.5  109 /L was on day 20 and Median time of platelet recovery
20 109 /L was on day25. At present 34 out of 43 are alive and
9 patients died due to aGVHD, cGVHD, rejection, veno-occlusive
disease, infection and the others. Thirty-two patients (74.4%)
developed aGVHD (grade I  9, grade II  7, grade III  11,
grade IV  5). Seventeen patients (39.5%) developed cGVHD
(limited  5, extensive  12). Eight year disease free survival in
class 3 and 2 were 71% and 63%, respectively (p  0.3).Eight year
overall survival in class 3 and 2 were 78% and 79%, respectively
(p  0.00). Conclusion: According to this study, for an acceptable
outcome in thalassemia class3. We need better conditioning and
GVHD prophylaxis regimens to decrease cardiopulmonary and
liver complications. The results of blood and marrow transplanta-
tion showed that it is better than supportive therapy such as
transfusion and desferal therapy.
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CELIAC DISEASE TRANSMITTED BY CORD BLOOD STEM CELL TRANS-
PLANTATION (CBST)
Baothman, A.A.1, Correa, H.2, Brown, R.2, Yu, L.C.2 1. King Faisal
Specialist Hospital, Riyadh, Centeral, Saudi Arabia; 2. Louisiana State
University, NewOrleans, LA
Either BMT or CBST could transmit immune associated dis-
eases such as diabetes mellitus, immune thrombocytopenic purpura
and complex autoimmune diseases with Evan’s syndrome and
transverse myelitis. We observed the occurrence of Celiac disease
a year following cord blood stem cell transplantation (CBST) for
acute myelogenous leukemia (AML-FAB M2) in complete second
remission (CR-2). Patient had not suffered celiac disease prior to
CBST and none of family member suffered too. The cord donor
was HLA-identical unrelated male donor with HLA types: A3, B7
(w6), DR (B1), DR (B5), HLA DQ A1.0501 and DQ B1.0201
alleles family history was not available for celiac disease. CBST
complicated with grade 2 skin Graft versus Host Disease (GVHD),
which responded to steroid therapy, a year post transplantation she
developed persistent mucous diarrhea with tinge of blood associ-
ated with abdominal cramps, work up of infectious causes and
studies for CMV enteritis were negative, colonsocopy revealed no
GVHD, gastrointestinal symptoms persist and failed to respond to
steroid and prograf therapy, duodenal and jejunal biopsy revealed
subtotal villous atrophy with cryptic hyperplasia which was sug-
gestive of celiac disease, in addition to, antigliadin IgA, IgG, reti-
culin IgA, and Endomysial IgA antibodies were elevated. She
responded well to gluten-free diet and was symptom-free. Possible
causes of her autoimmune illness were 1) transference of autoim-
mune cells from the donor and 2) patient’s predisposition to au-
toimmune disease secondary to an dysregulated immune system
because of myeloablative therapy. Celiac disease is intolerance to
certain cereal grains causing small bowel villous atrophy and thus
malabsorption. Speciﬁcally, the gliadin component of wheat, and
the prolamin component of rye and barley are implicated in caus-
ing disease by binding to HLA-II class molecules in APC and
hence elicit an immune reaction. Celiac disease is associated with
an increased risk for non-Hodgkin lymphoma, especially of T-cell
type. The propensity to develop T-cell non-Hodgkin lymphoma
and transmission of celiac disease by CBST support T cell concept
in celiac disease. Celiac disease is strongly associated with some
HLA-class II types, including DQA1.0501, and DQB1.0201, in
conjunction with the haplotypes A30, B18, DR3, DRw52, and
DQ2. Autoimmune enteropathy should be considered in HLA-
high risk patients with persistent diarrhea post Stem Cell Trans-
plantation.
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A NOVEL CONDITIONING REGIMEN OF IMMUNE SUPPRESSION WITH
CAMPATH-1H, FLUDARABINE AND MELPHALAN IN STEM CELL TRANS-
PLANTATION FOR NON-MALIGNANT DISORDERS
Barnes, Y.1, Hayashi, R.2, Yu, L.3, DiPersio, J.2, Grossman, W.2,
Witty, S.2, Heigham, M.1, Trinkhaus, K.2, Shenoy, S.2 1. St. Louis
Children’s Hospital, St. Louis, MO; 2. Washington University School of
Medicine, St. Louis, MO; 3. Louisiana State University School of
Medicine, New Orleans, LA
Successful allogeneic stem cell transplantation (SCT) beneﬁts
many non-malignant disorders. Factors limiting successful trans-
plantation for these conditions are lack of HLA matched donors,
toxicities of conditioning, graft rejection, and graft versus host
disease (GVHD). Based on the hypothesis that intense immuno-
suppression targeted at host lymphocytes would allow successful
engraftment of stem cells irrespective of source, we used campath-
1H, ﬂudarabine and melphalan in a novel fashion as conditioning
in a pilot transplant trial for non-malignant disorders. Cam-
path-1H (48 mg total) was administered once daily over 3 days
(-21, -20 and -19), ﬂudarabine (30 mg/m2/day) for 5 days (-8 to -4),
and melphalan (140mg/m2) on day -3. The timing of campath-1H
was designed to deplete recipient lymphocytes and macrophages,
without prolonged immunosuppression of the graft. GVHD pro-
phylaxis was CSA or FK506 (tapered after 3 months), steroids (1
mg/kg) from day -7 (tapered after 1 month), and short course
methotrexate (day 1 [10 mg/m2], 3 and 6 [7.5 mg/m2] except
in cord transplants). Primary end points of the study were engraft-
ment and treatment related mortality (TRM) at 100 days. The
regime was tolerated well. The ﬁrst 10 recipients are described in
table 1. Several recipients with BM failure syndromes were trans-
planted after several platelet and PRBC transfusions, putting them
at high risk for graft rejection. Median follow up was 4 months;
range 1-18m. Neutrophils (ANC 500)/cu.mm) engrafted at 12
days (range 8-20d); platelets (50K/cu mm) engrafted at 22 days
(21-30d). Serial immune reconstitution studies revealed profound
lymphopenia at 1 month (ALC; NK; T and B cells), recovering
after the third month, normalizing at 9 months. Five are off
steroids; 2 are off all immunosuppression. All had stable or im-
proved disease parameters. Post transplant complications were
predominantly infections. All CMV  recipients (n  4) reacti-
vated CMV in  30 days but responded to preemptive therapy.
Others included HHV6 (2) and bacterial (7). One UCB recipient
developed grade 3 toxicity due to CMV disease and TTP, and died
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